~2% with placebo) and broad improvements in cardiometabolic risk profiles, including glycemia, blood pressure, lipid levels, and inflammatory biomarkers
Gonzalez-Barcala FJ, Pertega S, Perez Castro T, Sampedro M, Sanchez Lastres J, San Jose Gonzalez MA, et al
Today is the Worst GLP1s+ Will Ever Be GLP1s+ More effective (5% to 22% weight loss and on their way to 25%+) More expansive disease management (diabetes, obesity, CVD, CKD, OSA, and studied for more) Less frequent (2x per day to 1x week and on their way to 1x/month to 1x/year?) Additional effective options in orals are on their way Insurance Coverage Medicare adding coverage for CVD (hopefully more diseases on the way as labels expand) Medicaid added 5 states in just 2023 Federal government added all employees and family members in 2023 Commercial employer coverage increased by 35% in 2023, with more employers considering it The Treat and Reduce Obesity Act (TROA) has been introduced in Congress to encourage Medicare coverage Costs Zepbound, a more effective drug, launched ~20-30% cheaper than Wegovy, with a savings card that put it at just over 1/3rd of the price at the time
The risk is the same here, too